CD27 is a member of the tumor necrosis factor receptor superfamily. It is expressed on the surface of T and B cells, and is very important for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. Administration of an agonistic anti-CD27 antibody can effectively enhance the antitumor immunity effect for lymph cancer and B16 melanoma, providing putative targets for tumor immunological therapies.
mRNA expression verification:
Fig 1. Molecular identification of the B-hCD27 humanized mice. Mouse CD27 mRNA was detected in both the wild type and the B-hCD27 heterozygous mice, while human CD27 mRNA was detected only in the B-hCD27 heterozygous mice.
Protein expression verification:
Fig 2. B-hCD27 humanized mice spleen cell activation and flow cytometry.
mCD27+ cells were detected in C57BL/6 mice and B-hCD27 heterozygous mice. hCD27+ cells were detected in B-hCD27 heterozygous mice.
CD27 antibody efficacy validation:
Fig 3. B-hCD27 mice were used for hCD27 antibody efficacy validation. Mouse colon cancer MC38 cells were subcutaneously transplanted into B-hCD27 heterozygous mice, and animals were grouped into control to treatment groups (n=5) when the tumor size is approximately 100 mm3. Anti-hCD27 antibody shows substantially inhibitory effects. The average±SEM of tumor sizes are shown in the figure. B-hCD27 mice are effective tools for hCD27 antibody efficacy validation.